|3rd September 2020||Scott E. Royer||500||Exercise of derivative||$3.90||$1,950.00|
|27th July 2020||John E. Leonard||1,000||Exercise of derivative||$3.90||$3,900.00|
|10th July 2020||Albert Friedberg||1,126,760||Open or private purchase||$3.55||$3,999,998.00|
|30th March 2020||Albert Friedberg||5,000||Open or private purchase||$4.06||$20,300.00|
|27th March 2020||Albert Friedberg||4,000||Open or private purchase||$4.18||$16,720.00|
|26th March 2020||Albert Friedberg||1,000||Open or private purchase||$4.44||$4,440.00|
|24th March 2020||Albert Friedberg||2,000||Open or private purchase||$4.40||$8,800.00|
|20th March 2020||Albert Friedberg||2,000||Open or private purchase||$4.31||$8,620.00|
|19th March 2020||Albert Friedberg||4,000||Open or private purchase||$4.15||$16,600.00|
|17th March 2020||Albert Friedberg||3,440||Open or private purchase||$4.00||$13,760.00|
Based on disclosure changes, sentiment, insider trading and news impact we give a rating of 9/10.
Vaccinex, Inc. is a clinical-stage biotechnology company. Its products pipeline include SEMA4D antibody platform and ActivMAb antibody discovery platform. The company was founded by Maurice Zauderer and Deepak Sahasrabudhe in 1997.